(iv) Diagnosis of diseases includes animals used in direct diagnosis of diseases such as rabies, botulism, but excluding those covered under regulatory use.

iv. Diagnosis of diseases includes animals used in direct diagnosis of diseases such as rabies, botulism, but excluding those covered under regulatory use.

Set up a Working Group on Pharmaceuticals and Biotech and in this framework they agree to hold experts’ meetings, as a matter of priority, with the participation of European Agency for Evaluation of Medicinal Products (EMEA) on the EU regulatory approach in the field of Ayurveda products; Exchange information on the regulatory framework, on best practice in funding, research, environmental issues, technical exchange programmes, and infrastructure support institutions; Cooperate on confronting global challenges posed by diseases such as HIV/AIDS, tuberculosis and malaria, and as p ...[+++]art of this seek to organise a Conference on development of vaccines for HIV/AIDS, malaria and tuberculosis.

Examples of policy measures taken since 2001 include the funding of genome research to fight antibiotic resistance; the establishment of a joint EU surveillance and early warning networks for communicable diseases; the adoption of a proposal for a new EU regulatory framework for chemicals (REACH); the adoption of the European Environment and Health Action Plan 2004-2010; and the setting up of a European Food Safety Authority (EFSA) and European Centre on Communicable Diseases (ECDC).

Annex Aspects to be considered (1) The definition of an "orphan drug" (2) The definition of a "rare disease", having regard to its prevalence (3) The criteria for obtaining "orphan drug" status in Europe, establishing conditions for drugs' inclusion or exclusion, in the light of any changes in the conditions on the basis of which they were classified (4) Measures using regulatory provisions (including intellectual property aspects) and financial incentives to promote research, development, marketing authorization and distribution of orphan drugs (5) Examination of the health impact of a European policy on orphan drugs in the Member State ...[+++]s and its economic impact for European industry".

The Regulation applies to all legislation relating to the social security branches concerning sickness and maternity benefits, invalidity benefits, old age benefits, survivors’ benefits, benefits in respect of accidents at work and occupational diseases, unemployment benefits, family benefits and death grants.